HC Wainwright & Co. Reiterates Buy on Revolution Medicines, Maintains $195 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 90.4%

Neg 0% Neu 90.4% Pos 0%

HC Wainwright & Co. analyst Robert Burns reiterates Revolution Medicines (NASDAQ:RVMD) with a Buy and maintains $195 price target.